Shares of CASI Pharmaceuticals Inc. (CASI) surged 40% to $4.99 in premarket trading today, in response to a preliminary non-binding offer to purchase the company's entire China-based operations.
On June 21, 2024, Dr. Wei-Wu He, Chairman of the Board and CEO, submitted a proposal to acquire the entire business operations of the company in China, along with all license-in, distribution, and related rights in Asia (excluding Japan) for its pipeline products.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com